These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 8913541)

  • 21. New angiotensin-II blocker.
    Lilley LL; Guanci R
    Am J Nurs; 1996 Mar; 96(3):20. PubMed ID: 8607540
    [No Abstract]   [Full Text] [Related]  

  • 22. Angiotensin II antagonism: a new avenue of hypertension management.
    Gavras H
    Blood Press Suppl; 1997; 1():42-6. PubMed ID: 9285108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
    Burnier M; Brunner HR
    Exp Nephrol; 1996; 4 Suppl 1():41-6. PubMed ID: 9001896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Angiotensin receptor antagonists. A new class of antihypertensive agents].
    Mann J
    Dtsch Med Wochenschr; 1996 Apr; 121(17):568-71. PubMed ID: 8620827
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical experience with angiotensin II receptor antagonists.
    Lee RJ; Brunner HR
    J Hum Hypertens; 1993 Aug; 7 Suppl 2():S33-6. PubMed ID: 8230087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective antagonism of the AT1 receptor inhibits the effect of angiotensin II on DNA and protein synthesis of rat proximal tubular cells.
    Weerackody RP; Chatterjee PK; Mistry SK; McLaren J; Hawksworth GM; McLay JS
    Exp Nephrol; 1997; 5(3):253-62. PubMed ID: 9208286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers].
    Pichler M; Klein W; Huber K; Pachinger O
    Wien Med Wochenschr; 1996; 146(11):228-31. PubMed ID: 8928520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy].
    Krasnikova TL
    Klin Med (Mosk); 1996; 74(3):17-21. PubMed ID: 8926692
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of angiotensin receptor blockade in the rabbit aorta: influence of the endothelium.
    le Tran Y; Forster C
    Can J Physiol Pharmacol; 1996 Dec; 74(12):1277-86. PubMed ID: 9047036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Losartan, a nonpeptide angiotensin II receptor antagonist, on norepinephrine overflow and antidiuresis induced by stimulation of renal nerves in anesthetized dogs.
    Suzuki Y; Matsumura Y; Egi Y; Morimoto S
    J Pharmacol Exp Ther; 1992 Dec; 263(3):956-63. PubMed ID: 1469652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medical angiotensin II-receptor blockade in hypertension and heart failure].
    van Zwieten PA; Lie KI
    Ned Tijdschr Geneeskd; 1995 Jul; 139(30):1529-33. PubMed ID: 7675129
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
    Brooks DP; Ruffolo RR
    J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-formylmethionyl-leucyl-phenylalanine to neutrophil receptors.
    Raiden S; Giordano M; Andonegui G; Trevani AS; López DH; Nahmod V; Geffner JR
    J Pharmacol Exp Ther; 1997 May; 281(2):624-8. PubMed ID: 9152365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men.
    Goldberg MR; de Mey C; Wroblewski JM; Li Q; Schroeter V; Belz GG
    Clin Pharmacol Ther; 1996 Jan; 59(1):72-82. PubMed ID: 8549037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
    Mallion JM; Goldberg AI
    Blood Press Suppl; 1996; 2():82-6. PubMed ID: 8913546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Angiotensin-2 receptor blockade--new therapeutic approach to treatment of hypertension].
    Zimlichman R
    Harefuah; 1996 Jul; 131(1-2):43-5. PubMed ID: 8854479
    [No Abstract]   [Full Text] [Related]  

  • 38. The role of angiotensin II receptors and their antagonists in hypertension.
    van Zwieten PA
    Ann Ital Med Int; 2000; 15(1):85-91. PubMed ID: 10842896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Angiotensin II receptor antagonists].
    Bornkessel B
    Med Monatsschr Pharm; 1995 Jun; 18(6):148-51. PubMed ID: 7609710
    [No Abstract]   [Full Text] [Related]  

  • 40. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK; Sodhi RK; Singh M
    Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.